Treatment of inflammatory bowel disease using fibroblast growth factor CX polypeptides
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Mar 13, 2007
Grant Date -
Jan 8, 2004
app pub date -
Dec 16, 2002
filing date -
Nov 6, 2000
priority date (Note) -
Expired
status (Latency Note)
Importance
Abstract
The present invention is based upon methods of treating inflammatory conditions in the intestinal tract of mammals using growth factor related polypeptides. The invention includes methods of reducing the mortality rate or delaying mortality in a subject suffering from an inflammatory pathology. Methods of using fibroblast growth factor-CX (FGF-CX) polynucleotides sequences and the FGF-CX polypeptides encoded by such nucleic acid sequence, or variants, fragments and homologs thereof, are claimed in the invention. Similarly, methods of using FCTRX polynucleotide sequences and the FCTRX polypeptides encoded by such nucleic acid sequences, or variants, fragments and homologs thereof, alone or in combination, are also claimed in the invention. FCTRX collectively refers to any of six variant FCTRX sequences, variously designated FCTR1, FCTR2, FCTR3, FCTR4, FCTR5 and FCTR6.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully